Shares of Arcturus Therapeutics slid 7.67% to $33.22 at 14:49 EST on Tuesday, after five consecutive sessions in a row of losses. NASDAQ Composite is falling 2.48% to $13,550.11, after two consecutive sessions in a row of losses. This seems, so far, an all-around rough trend trading session today.

Arcturus Therapeutics’s last close was $35.98, 290.46% below its 52-week high of $129.71.

Arcturus Therapeutics’s Sales

Arcturus Therapeutics’s sales growth is a negative 4% for the ongoing quarter and a decline by 28% for the next. The company’s growth estimates for the present quarter and the next is a negative 86.6% and a negative 163.6%, respectively.

Arcturus Therapeutics’s Revenue

Year-on-year quarterly revenue growth declined by 24.6%, now sitting on 9.54M for the twelve trailing months.

Arcturus Therapeutics’s Stock Yearly Top and Bottom Value

Arcturus Therapeutics’s stock is valued at $33.22 at 14:49 EST, way below its 52-week high of $129.71 and way higher than its 52-week low of $13.09.

Arcturus Therapeutics’s Moving Average

Arcturus Therapeutics’s worth is way under its 50-day moving average of $50.01 and way under its 200-day moving average of $62.10.

More news about Arcturus Therapeutics.


Please enter your comment!
Please enter your name here